Immune-Mediated Inflammatory Diseases (IMIDs) afflict millions of people in the midst of working life, driving billions of dollars in healthcare costs, and new therapies are desperately needed
Our Vision: to drive changes to traditional drug discovery and treatment strategies by employing state-of-the-art methods and technologies to deeply understand patients and their underlying conditions
Our Mission: to partner with Pharma, Health companies, Payers, Big Data and Physicians to develop precision medicine diagnostics and new therapeutics that optimize treatment of IMID patients
Standardized collection of clinical data by physicians is critical to reliable diagnosis of patients’ condition.
The cornerstone of a reliable biomedical research is the availability of high-quality biological samples.
High precision characterization of multiple molecular biomarkers, combined with reliable clinical data, is fundamental to accurately profile the patient condition.
IMIDomics portal is a proprietary tool that has been built specifically to integrate our data and allow in-depth inquiries
IMID Clinical Consortium
Cross-sectional IMID Grant Awarded
ISO 9001 Certification
First Cohort Collected
Hudsonalpha Institute for Biotechnology Partnership
Analysis and Database Build
Longitudinal IMID cohort grant awarded
Continued Cohort Collection and Analysis
H2020 EU Framework Grant